PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. Read More The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ. The listed name for PDSB is PDS Biotechnology Corporation Common Stock.